Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2024

Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2024

DelveInsight’s, “Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Protein tyrosine phosphatase non receptor type 11 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Protein tyrosine phosphatase non receptor type 11 antagonists Understanding

Protein tyrosine phosphatase non receptor type 11 antagonists: Overview

Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) also known as protein-tyrosine phosphatase 1D (PTP-1D), Src homology region 2 domain-containing phosphatase-2 (SHP-2), or protein-tyrosine phosphatase 2C (PTP-2C) is an enzyme that in humans is encoded by the PTPN11 gene. PTPN11 is a protein tyrosine phosphatase (PTP) Shp2. PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. More recently, there has been renewed interest in developing inhibitors of the tyrosine phosphatase SHP2 (PTPN11) in the light of its broad role in cancer, specifically juvenile myelomonocytic leukemia, and recent studies that implicate SHP2 as a key factor in breast cancer progression.

""Protein tyrosine phosphatase non receptor type 11 antagonists - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Protein tyrosine phosphatase non receptor type 11 antagonists pipeline landscape is provided which includes the disease overview and Protein tyrosine phosphatase non receptor type 11 antagonists treatment guidelines. The assessment part of the report embraces, in depth Protein tyrosine phosphatase non receptor type 11 antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Protein tyrosine phosphatase non receptor type 11 antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Protein tyrosine phosphatase non receptor type 11 antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Protein tyrosine phosphatase non receptor type 11 antagonists.

Protein tyrosine phosphatase non receptor type 11 antagonists Emerging Drugs Chapters

This segment of the Protein tyrosine phosphatase non receptor type 11 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Protein tyrosine phosphatase non receptor type 11 antagonists Emerging Drugs

• RMC-4630: Revolution medicines

RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway currently being evaluated in Phase II stage of development for the treatment of Non-Small cell lung cancer. The RMC-4630 program is the focus of an exclusive global research, development and commercialization agreement with Sanofi, under which the company received a $50 million upfront payment, and Sanofi agreed to cover all development costs and certain research costs for the joint SHP2 program. Sanofi received an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote right for Revolution Medicines.

• JAB-3068: Jacobio Pharmaceuticals

SHP2 is a ubiquitously expressed non-receptor tyrosine phosphatase that is activated upon interaction of the N-terminal SH2 domains with phosphorylated cell surface receptors (e.g., pRTKs, pPD-1, etc.) to transduce extracellular signals. SHP2 regulates survival and proliferation primarily via the RAS-ERK pathway, specifically RTK, NF1 loss, RAS, Class-III RAF-driven cancers depend on SHP2. SHP2 is also implicated in immune evasion via the PD-1 and BTLA immune checkpoint pathways. AbbVie has obtained from Jacobio Pharmaceuticals an exclusive global license, excluding greater China, to develop and commercialize JAB-3068 and JAB-3312.

Further product details are provided in the report……..

Protein tyrosine phosphatase non receptor type 11 antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Protein tyrosine phosphatase non receptor type 11 antagonists drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Protein tyrosine phosphatase non receptor type 11 antagonists

There are approx. 7+ key companies which are developing the therapies for Protein tyrosine phosphatase non receptor type 11 antagonists. The companies which have their Protein tyrosine phosphatase non receptor type 11 antagonists drug candidates in the most advanced stage, i.e. phase II include Revolution medicines.

● Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Protein tyrosine phosphatase non receptor type 11 antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Protein tyrosine phosphatase non receptor type 11 antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein tyrosine phosphatase non receptor type 11 antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein tyrosine phosphatase non receptor type 11 antagonists drugs.

Protein tyrosine phosphatase non receptor type 11 antagonists Report Insights

• Protein tyrosine phosphatase non receptor type 11 antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Protein tyrosine phosphatase non receptor type 11 antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Protein tyrosine phosphatase non receptor type 11 antagonists drugs?
• How many Protein tyrosine phosphatase non receptor type 11 antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Protein tyrosine phosphatase non receptor type 11 antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Protein tyrosine phosphatase non receptor type 11 antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Protein tyrosine phosphatase non receptor type 11 antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?